1. In Vivo

Covidien Runs Familiar But Different Plays to Build Vascular Franchise

Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.

By agreeing to pay $2.6 billion to acquire endovascular player ev3 Inc., Covidien Ltd. emphatically made two points. [See Deal] First, Covidien – now three years removed from its spin out of Tyco International Ltd. – is demonstrating a familiar pattern of growing through acquisitions, as it did under Tyco a decade ago. [See Deal] Second, Warburg Pincus and Vertical Group made a good call 10 years ago in backing the creation of ev3 to target vascular markets outside the coronary, at least in the eyes of one of the principals who started the company.

In building through buying, Covidien is working with a familiar playbook. As Tyco Healthcare Group, the company grew into a...

More from Archive

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.